These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 37541244)

  • 1. Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.
    de Miguel FJ; Gentile C; Feng WW; Silva SJ; Sankar A; Exposito F; Cai WL; Melnick MA; Robles-Oteiza C; Hinkley MM; Tsai JA; Hartley AV; Wei J; Wurtz A; Li F; Toki MI; Rimm DL; Homer R; Wilen CB; Xiao AZ; Qi J; Yan Q; Nguyen DX; Jänne PA; Kadoch C; Politi KA
    Cancer Cell; 2023 Aug; 41(8):1516-1534.e9. PubMed ID: 37541244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
    He T; Cheng C; Qiao Y; Cho H; Young E; Mannan R; Mahapatra S; Miner SJ; Zheng Y; Kim N; Zeng VZ; Wisniewski JP; Hou S; Jackson B; Cao X; Su F; Wang R; Chang Y; Kuila B; Mukherjee S; Dukare S; Aithal KB; D S S; Abbineni C; Vaishampayan U; Lyssiotis CA; Parolia A; Xiao L; Chinnaiyan AM
    Proc Natl Acad Sci U S A; 2024 Apr; 121(15):e2322563121. PubMed ID: 38557192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Bromodomains of the mammalian SWI/SNF (mSWI/SNF) ATPases Brahma (BRM) and Brahma Related Gene 1 (BRG1) promote chromatin interaction and are critical for skeletal muscle differentiation.
    Sharma T; Robinson DCL; Witwicka H; Dilworth FJ; Imbalzano AN
    Nucleic Acids Res; 2021 Aug; 49(14):8060-8077. PubMed ID: 34289068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
    Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
    Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Concepcion CP; Ma S; LaFave LM; Bhutkar A; Liu M; DeAngelo LP; Kim JY; Del Priore I; Schoenfeld AJ; Miller M; Kartha VK; Westcott PMK; Sánchez-Rivera FJ; Meli K; Gupta M; Bronson RT; Riely GJ; Rekhtman N; Rudin CM; Kim CF; Regev A; Buenrostro JD; Jacks T
    Cancer Discov; 2022 Feb; 12(2):562-585. PubMed ID: 34561242
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.
    Yochum ZA; Cades J; Wang H; Chatterjee S; Simons BW; O'Brien JP; Khetarpal SK; Lemtiri-Chlieh G; Myers KV; Huang EH; Rudin CM; Tran PT; Burns TF
    Oncogene; 2019 Jan; 38(5):656-670. PubMed ID: 30171258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer.
    Nguyen VT; Tessema M; Weissman BE
    Cancer Treat Res; 2023; 190():211-244. PubMed ID: 38113003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
    Vangamudi B; Paul TA; Shah PK; Kost-Alimova M; Nottebaum L; Shi X; Zhan Y; Leo E; Mahadeshwar HS; Protopopov A; Futreal A; Tieu TN; Peoples M; Heffernan TP; Marszalek JR; Toniatti C; Petrocchi A; Verhelle D; Owen DR; Draetta G; Jones P; Palmer WS; Sharma S; Andersen JN
    Cancer Res; 2015 Sep; 75(18):3865-3878. PubMed ID: 26139243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non-small cell lung cancer.
    Chang G; Li W; Bai H; Duan J; Wang Z; Du X; Yu R; Wang Y; Wang M; Zhu Y; Zhang X; Li L; Wan R; Wang J
    Thorac Cancer; 2022 Nov; 13(21):2951-2959. PubMed ID: 36126963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of function of SWI/SNF chromatin remodeling genes leads to genome instability of human lung cancer.
    Huang HT; Chen SM; Pan LB; Yao J; Ma HT
    Oncol Rep; 2015 Jan; 33(1):283-91. PubMed ID: 25370573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma.
    Song S; Nguyen V; Schrank T; Mulvaney K; Walter V; Wei D; Orvis T; Desai N; Zhang J; Hayes DN; Zheng Y; Major MB; Weissman BE
    Mol Cancer Res; 2020 Dec; 18(12):1777-1788. PubMed ID: 32855269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ATPase module of mammalian SWI/SNF family complexes mediates subcomplex identity and catalytic activity-independent genomic targeting.
    Pan J; McKenzie ZM; D'Avino AR; Mashtalir N; Lareau CA; St Pierre R; Wang L; Shilatifard A; Kadoch C
    Nat Genet; 2019 Apr; 51(4):618-626. PubMed ID: 30858614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evidence in the assembly of mammalian SWI/SNF complexes: Epigenetic insights and clinical perspectives in human lung disease therapy.
    Trejo-Villegas OA; Heijink IH; Ávila-Moreno F
    Mol Ther; 2024 Aug; 32(8):2470-2488. PubMed ID: 38910326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection.
    Wei J; Patil A; Collings CK; Alfajaro MM; Liang Y; Cai WL; Strine MS; Filler RB; DeWeirdt PC; Hanna RE; Menasche BL; Ökten A; Peña-Hernández MA; Klein J; McNamara A; Rosales R; McGovern BL; Luis Rodriguez M; García-Sastre A; White KM; Qin Y; Doench JG; Yan Q; Iwasaki A; Zwaka TP; Qi J; Kadoch C; Wilen CB
    Nat Genet; 2023 Mar; 55(3):471-483. PubMed ID: 36894709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Casein kinase 2-mediated phosphorylation of Brahma-related gene 1 controls myoblast proliferation and contributes to SWI/SNF complex composition.
    Padilla-Benavides T; Nasipak BT; Paskavitz AL; Haokip DT; Schnabl JM; Nickerson JA; Imbalzano AN
    J Biol Chem; 2017 Nov; 292(45):18592-18607. PubMed ID: 28939766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.
    Selenica P; Marra A; Choudhury NJ; Gazzo A; Falcon CJ; Patel J; Pei X; Zhu Y; Ng CKY; Curry M; Heller G; Zhang YK; Berger MF; Ladanyi M; Rudin CM; Chandarlapaty S; Lovly CM; Reis-Filho JS; Yu HA
    Ann Oncol; 2022 Dec; 33(12):1284-1295. PubMed ID: 36089134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia.
    Rago F; Rodrigues LU; Bonney M; Sprouffske K; Kurth E; Elliott G; Ambrose J; Aspesi P; Oborski J; Chen JT; McDonald ER; Mapa FA; Ruddy DA; Kauffmann A; Abrams T; Bhang HC; Jagani Z
    Mol Cancer Res; 2022 Mar; 20(3):361-372. PubMed ID: 34799403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.
    Lee TF; Tseng YC; Nguyen PA; Li YC; Ho CC; Wu CW
    Sci Rep; 2018 Jan; 8(1):271. PubMed ID: 29321482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer.
    Duplaquet L; So K; Ying AW; Pal Choudhuri S; Li X; Xu GD; Li Y; Qiu X; Li R; Singh S; Wu XS; Hamilton S; Chien VD; Liu Q; Qi J; Somerville TDD; Heiling HM; Mazzola E; Lee Y; Zoller T; Vakoc CR; Doench JG; Forrester WC; Abrams T; Long HW; Niederst MJ; Drapkin BJ; Kadoch C; Oser MG
    Cancer Cell; 2024 Aug; 42(8):1352-1369.e13. PubMed ID: 39029464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
    Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
    J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.